Phase 2
N=310
Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
Eczema · Allergy Symptoms · Psoriasis · Itch
Bottom Line
View on ClinicalTrials.gov: NCT02075632 ↗Enrolled (actual)
310
Serious AEs
0.3%
Results posted
Jul 2014
Primary outcome: Primary: Number of Participants With Incorrect Duration of Use of the Medication — 97; 89 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Alclometasone dipropionate cream (Drug)
- Age
- Pediatric, Adult, Older Adult · 12+ yrs
- Sex
- All
- Sponsor
- GlaxoSmithKline
- Primary completion
- Nov 2006
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Incorrect Duration of Use of the Medication |
97; 89 | — |
| SECONDARY Number of Times Per Day Participants Used the Product |
1.95; 1.92; 2.6; 2.7 | — |
| SECONDARY Number of Days of Use |
12.5; 11.8 | — |
Summary
This is a multi-center, open-label study to evaluate whether participants follow the duration of use instructions for short-term use of alclometasone dipropionate in a population of participants with itchy skin conditions who would use OTC treatments for relief. The study population will be composed of two different cohorts: chronic condition sufferers (eczema or psoriasis) and participants who suffer from occasional itchy skin experiences (such as poison ivy, oak, sumac, insect bites, or skin irritations due to jewelry, cosmetics, detergents, or soaps) where an anti-itch medication would be used.
Eligibility Criteria
Inclusion Criteria
- Age: At least 12 years of age.
- Condition: Currently experiencing itch associated with one of the following skin conditions:
- psoriasis or eczema,
- minor skin conditions such as those caused by poison ivy, oak, or sumac, insect bites, or use of cosmetics, soaps, detergents, or jewelry.
- Compliance: Subject or subject's parent or legal guardian understands and is willing, able and likely to comply with all study procedures and restrictions.
- Consent: Subject or subject's parent or legal guardian demonstrates ability to read and understand English and is willing to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form (and assent as appropriate).
Exclusion Criteria
- Pregnancy: Women who are known to be pregnant (as self-reported) or who are intending to become pregnant over the duration of the study. Women of childbearing potential will be allowed to participate in the study so long as they are practicing a reliable method of contraception (e.g. hormonal birth control such as pill, patch, implant or injection; intrauterine device, double barrier methods, tubal ligation, vasectomized spouse or abstinence).
- Corticosteroid Use: Subject has used a corticosteroid treatment within two weeks of the screening visit at the start of the study.
- Breast-feeding: Women who are breastfeeding.
- Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to alclometasone cream (or closely related compounds), or any of their stated ingredients.
- Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit at the start of the study.
Data sourced from ClinicalTrials.gov (NCT02075632). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.